Assessment of the temporal trends of humoral and cell-mediated immune responses to SARS-CoV-2 mRNA vaccines among multiple sclerosis patients treated with immunomodulatory therapies
Latest Information Update: 06 Jun 2022
At a glance
- Drugs Dimethyl fumarate (Primary) ; Diroximel-fumarate (Primary) ; Natalizumab (Primary) ; Ocrelizumab (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 06 Jun 2022 New trial record
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022